Tetra Jumps on Cancer Drug Tests

By: Tomas Ronolski - AllPennyStocks.com News

Tuesday, December 10, 2019

It’s the very thing patients need to hear as Christmas time approaches; more developments were published today on the fight against cancer.

Ottawa-based Tetra Bio-Pharma Inc. (TSX-Venture:TBP) is trumpeting its status as a leader in cannabinoid-derived drug discovery and development. Tuesday, it announced it will be requesting a meeting with the U.S. Food and Drug Administration (FDA) to discuss the drug development program for its Orphan Drug candidate HCC011, inhaled delta-9-tetrahydrocannabinol (THC), in the treatment of hepatocellular carcinoma.

Hepatocellular carcinoma (HCC), also known as primary liver cancer, is the most common form of liver cancer and is responsible for 80% of the primary malignant liver tumors in adults. In addition to quality of life benefits to cancer patients, based on preclinical research, HCC011 should also have anti-tumor effects.

Tuesday’s news release indicated the Phase 2 study of HCC011 will target patients with disease progression on Sorafenib, have measurable disease, and Child-Pugh Class A liver impairment.

The Phase 2 trial will consist of a single arm. Patients will receive the HCC011 by inhalation three times daily, in combination with Sorafenib, until disease progression or unacceptable toxicity.

Shares in TBP gained 2.5 cents, or 5.4%, to 48.5 cents, on volume of 434,000

Copyright © 2019 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon